Mark Lakshmanan
Overview
Explore the profile of Mark Lakshmanan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
1478
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gerstein H, Lee S, Pare G, Bethel M, Colhoun H, Hoover A, et al.
Diabetes Care
. 2023 Mar;
46(5):1046-1051.
PMID: 36897834
Objective: The glucagon-like peptide-1 receptor agonist dulaglutide reduced MACE in the Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial. This article expores the relationship of selected biomarkers...
2.
Branch K, Dagenais G, Avezum A, Basile J, Conget I, Cushman W, et al.
Eur J Heart Fail
. 2022 Sep;
24(10):1805-1812.
PMID: 36073143
Aims: People with diabetes are at high risk for cardiovascular events including heart failure (HF). We examined the effect of the glucagon-like peptide 1 agonist dulaglutide on incident HF events...
3.
Gerstein H, Ramasundarahettige C, Avezum A, Basile J, Conget I, Cushman W, et al.
Cardiovasc Diabetol
. 2022 Aug;
21(1):158.
PMID: 35996147
Background: The estimated glomerular filtration rate (eGFR) and the albumin-to-creatinine ratio (ACR) are risk factors for diabetes-related outcomes. A composite that captures information from both may provide a simpler way...
4.
Cukierman-Yaffe T, Gerstein H, Basile J, Bethel M, Cardona-Munoz E, Conget I, et al.
J Clin Endocrinol Metab
. 2022 Apr;
107(8):e3448-e3454.
PMID: 35446415
Context: Low cognitive scores are risk factors for cardiovascular outcomes. Whether this relationship is stronger using novel cognitive indices is unknown. Methods: Participants in the Researching Cardiovascular Events with a...
5.
Bajaj H, Gerstein H, Rao-Melacini P, Basile J, Colhoun H, Conget I, et al.
Lancet Diabetes Endocrinol
. 2021 Jun;
9(8):484-490.
PMID: 34153269
Background: Diabetes is a major risk factor for erectile dysfunction, however, the effect of GLP-1 receptor agonists on erectile dysfunction is unknown. We aimed to assess the incidence, prevalence, and...
6.
Riddle M, Gerstein H, Xavier D, Cushman W, Leiter L, Raubenheimer P, et al.
J Clin Endocrinol Metab
. 2021 Feb;
106(5):1345-1351.
PMID: 33537745
Context: Dulaglutide reduced major adverse cardiovascular events (MACE) in the Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial. Its efficacy and safety in older vs younger patients...
7.
Dagenais G, Ryden L, Leiter L, Lakshmanan M, Dyal L, Probstfield J, et al.
Cardiovasc Diabetol
. 2020 Nov;
19(1):199.
PMID: 33239067
Background: The Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) double blind randomized trial demonstrated that weekly subcutaneous dulaglutide 1.5 mg, a glucagon like peptide-1 receptor agonist, versus...
8.
Ferrannini G, Gerstein H, Colhoun H, Dagenais G, Diaz R, Dyal L, et al.
Eur Heart J
. 2020 Nov;
42(26):2565-2573.
PMID: 33197271
Objective: Recent European Guidelines for Diabetes, Prediabetes and Cardiovascular Diseases introduced a shift in managing patients with type 2 diabetes at high risk for or established cardiovascular (CV) disease by...
9.
Cukierman-Yaffe T, Gerstein H, Colhoun H, Diaz R, Garcia-Perez L, Lakshmanan M, et al.
Lancet Neurol
. 2020 Jun;
19(7):582-590.
PMID: 32562683
Background: Diabetes is an independent risk factor for cognitive impairment. We aimed to investigate the association between the glucagon-like peptide-1 (GLP-1) receptor agonist dulaglutide and cognitive impairment as an exploratory...
10.
Gerstein H, Hart R, Colhoun H, Diaz R, Lakshmanan M, Botros F, et al.
Lancet Diabetes Endocrinol
. 2020 Jan;
8(2):106-114.
PMID: 31924562
Background: Cardiovascular outcome trials have suggested that glucagon-like peptide 1 (GLP-1) receptor agonists might reduce strokes. We analysed the effect of dulaglutide on stroke within the researching cardiovascular events with...